Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Apr 26, 2024 12:01am
102 Views
Post# 36008652

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takes

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takesI do not fear Marathon, but I do respect their authority in this situation.  It's real, but the last thing they want to do is foreclose.  They will, but only if they have too.  They'll try to work it out first.  Dubuc already failed us by breaking financial covenants.  I can tell by his style of financial reporting, he's simply a bean counter, and lacks strategic vision and leadership.  He's learned a few things, because he's had access to resources over the years, but it wasn't enough to avoid extremely poor decisions.  I've seen middle management provide better leadership than Levesque.  He's an overpaid salesman chasing the next shiny object in hopes to keep everyone from holding him accountable.  Between you, Soleus, and IQ, you all could have a new, more qualified board in place tomorrow.  It would only be natural that you all work together representing close to 45% of the total shareholder interest.  I'm sure the rest of us would join you, and likley get that additional 6% to constitute a majority.  In this situation, Marathon has less leverage, because they need a leadership team to apply leverage.  Without one, they have less leverage.  
<< Previous
Bullboard Posts
Next >>